A single-blind, phase IV UK multi-centre randomised controlled trial to determine reactogenicity and immunogenicity of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Total publications:3 publications

Grant number: NIHR203243

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2025
  • Known Financial Commitments (USD)

    $4,168,302.42
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    University Hospitals Bristol and Weston NHS Foundation Trust
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 3 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Mass vaccination against COVID-19 started in the UK in early December 2020 and is likely to continue until mid-2021. Whilst rates of COVID-19 infection have decreased, the emergence of variants of interest and planned easing of lockdown measures has led to predictions of potential resurgence of infection from autumn 2021. The duration of protection of the current COVID-19 vaccines is unknown but it may be that further booster doses will be required in 9 to 12 months time with current or potentially strain-modified vaccines to afford continued protection into the autumn. The timing of the booster doses is likely to coincide with seasonal influenza vaccination, which is usually September to February. Delivering COVID-19 and influenza vaccines at separate appointments will cause significant logistical challenges therefore it would be desirable to immunise with both vaccines at the same appointment, in different arms. The ComFluCOV trial will determine the safety, as well as the immune responses, to administration of the currently approved COVID-19 vaccines at the same time as the recommended influenza vaccines from the 2020/21 season. Participants who are having their second COVID-19 vaccine will be randomised into two groups; one group will receive the influenza vaccine and the other group will receive saline (placebo) at the same time as the COVID-19 vaccine. Participants will not know whether they receive the influenza vaccine or the placebo. After 3 weeks participants who received the influenza vaccine will receive the saline injection and participants who received the saline injection will receive the influenza vaccine. Participants will be followed up for a further 3 weeks after the second injection. We hope to recruit 504 participants into the trial. The trial will be conducted in at least 5 UK NHS centres. The trial is expected to take about 6 months to complete.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Working under short timescales to deliver a national trial: a case study of the ComFluCOV trial from a statistician's perspective.

Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV).

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.